Vol. 1 No. 9: 3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, October 14-16, 2005

Published: 2009-06-03

Articles

The scale of the problem

M H Prins

https://doi.org/10.4081/hmr.v1i9.309

114

PDF: 139
- PDF
Occult cancer and idiopathic venous thromboembolism

A Piccioli

https://doi.org/10.4081/hmr.v1i9.310

140

PDF: 591
- PDF
Tissue factor-bearing microparticles and cancer-associated thrombosis

B Furie

https://doi.org/10.4081/hmr.v1i9.311

181

Untitled (): 0
Blood-borne tissue factor

NS Key

https://doi.org/10.4081/hmr.v1i9.312

203

PDF: 244
- PDF
Tissue factor pathway inhibitor and cancer

Y Gruel, J Rollin, S Regina, S Iochmann, F Hube, P Reverdiau

https://doi.org/10.4081/hmr.v1i9.313

139

PDF: 574
- PDF
Tissue factor-PAR2 signaling crosstalk in cancer and angiogenesis

W Ruf

https://doi.org/10.4081/hmr.v1i9.314

149

PDF: 412
- PDF
Oncogenic events regulating tissue factor expression

Y Yu, L May, V Lhotak, C Milsom, Y Li, S Shahrzad, S Shirasawa, JI Weitz, BL Coomber, J Micelef, A Guha, P Klement, N Klement, JW Rak

https://doi.org/10.4081/hmr.v1i9.315

140

PDF: 279
- PDF
Hemostatic factors support metastasis by impeding NK cell-mediated elimination of embolic tumor cells

JL Degen, JV Massari, KE Talmage, CM La Jeunesse, KW La Jeunesse, MJ Flick

https://doi.org/10.4081/hmr.v1i9.316

184

PDF: 311
- PDF
The met oncogene drives a genetic program linking cancer to hemostasis

C Boccaccio, PM Comoglio

https://doi.org/10.4081/hmr.v1i9.317

130

PDF: 217
- PDF
Cytokine GRO-a is pivotal in thrombin-induced angiogenesis

S Karpatkin

https://doi.org/10.4081/hmr.v1i9.318

150

PDF: 316
- PDF
Low molecular weight heparin and survival in cancer

AK Kakkar

https://doi.org/10.4081/hmr.v1i9.319

143

PDF: 152
- PDF
Fibrinolytics, enzyme inhibitors, and cancer survival

M Schmitt, V Magdolen, K Mengele, U Reuning, J Foekens, EP Diamandis, N Harbeck

https://doi.org/10.4081/hmr.v1i9.320

141

PDF: 633
- PDF
Vitamin k, warfarin and prothrombin: an alternate pathway to improve cancer survival

HA Liebman

https://doi.org/10.4081/hmr.v1i9.321

148

PDF: 216
- PDF
Future perspective of clinical trials of antithrombotics and cancer survival

R Er

https://doi.org/10.4081/hmr.v1i9.322

116

PDF: 147
- PDF
Clinical trials with angiogenesis inhibitors

G Giaccone, H van Cruijsen

https://doi.org/10.4081/hmr.v1i9.323

145

PDF: 155
- PDF
Vascular complications of endothelium targeting therapies

F Rodeghiero, F Elice

https://doi.org/10.4081/hmr.v1i9.324

132

PDF: 143
- PDF
Commentary on thrombotic and bleeding complications of clinical trials of growth factor inhibitors

CM Kessler

https://doi.org/10.4081/hmr.v1i9.325

111

PDF: 674
- PDF
Lymphangiogenesis: a new paradigm for cancer progression and therapy

K Alitalo

https://doi.org/10.4081/hmr.v1i9.326

107

PDF: 138
- PDF
Hemorrhage and thrombosis in acute leukemia

T Barbui

https://doi.org/10.4081/hmr.v1i9.327

360

PDF: 3570
- PDF
Prevention of disseminated intravascular coagulation in cancer

M Levi

https://doi.org/10.4081/hmr.v1i9.328

365

PDF: 1256
- PDF
Bleeding and thrombosis in childhood cancer

U Nowak-Gött

https://doi.org/10.4081/hmr.v1i9.329

136

PDF: 619
- PDF
The protein C system in inflammation and cancer: a critical role for thrombomodulin

H Spronk, H Ten Cate

https://doi.org/10.4081/hmr.v1i9.330

132

PDF: 160
- PDF
Heparin effects in metastasis and Trousseau's syndrome: anticoagulation is not the primary mechanism

JL Stevenson, SH Choi, M Wahrenbrock, A Varki, NM Varki

https://doi.org/10.4081/hmr.v1i9.331

277

PDF: 179
- PDF
The impact of heparanase on cancer progression

I Vlodavsky, N Ilan, G Abboud-Jarrous, Y Nadir, B Brenner, A Naggi, C Pisano, B Casu

https://doi.org/10.4081/hmr.v1i9.332

155

PDF: 693
- PDF
Inhibition of tumor growth by heparins in vivo

SA Mousa

https://doi.org/10.4081/hmr.v1i9.333

113

PDF: 163
- PDF
Clinical outcomes in cancer patients with concurrent venous thromboembolism: findings from the RIETE registry

M Monreal, C Falgá, B Vilaseca, C Suárez, F Gabriel, C Carles Tolosa, J Montes

https://doi.org/10.4081/hmr.v1i9.334

168

PDF: 478
- PDF
Unresolved problems in venous thromboembolism treatment in cancer

A Agnelli, M Verso

https://doi.org/10.4081/hmr.v1i9.335

135

PDF: 364
- PDF
The role of new antithrombotics

HR Büller

https://doi.org/10.4081/hmr.v1i9.337

104

PDF: 83
- PDF
Modified Heparins as possible inhibitors of metastasis

L Borsig

https://doi.org/10.4081/hmr.v1i9.338

107

PDF: 337
- PDF

Proceedings

Hypercoaugulability

Anna Falanga, Benjamin Brenner, Frederick R Rickles

https://doi.org/10.4081/hmr.v1i9.339

290

PDF: 572
- PDF

© PAGEPress 2008-2024 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185 • Privacy